VEGFA and hepatocellular carcinoma: In the treatment of HCC, the main chemotherapeutics inhibit the multiple kinases involved in angiogenesis and tumor cell proliferation pathways by blocking receptor tyrosine kinases (RTKs), including vascular endothelial growth factor receptor (VEGF), platelet-derived growth factor receptor, fibroblast growth factor receptor, and mesenchymal–epithelial transition factor [16].